CHICAGO -- The bispecific T-cell engager tarlatamab (Imdelltra) significantly prolonged survival in the second-line treatment ...

DelveInsight’s Natural Killer (NK)-Cell Lymphoma Pipeline report depicts a robust space with 100+ active players working to develop 140+ pipeline therapies for Natural Killer (NK)-Cell Lymphoma ...

CAR T cell immunotherapy, which uses a patient's own modified immune cells to find and destroy cancer cells, can produce ...

The presentation will feature the design and objectives of the Phase 1 study, which marks the first clinical application of ...

The agent could be repurposed to treat various cancer types, including leukemia, lymphoma and breast ... “It doesn’t affect the body. It affects the cells that are rapidly dividing, and ...

An additional case of indolent CD4+ cytotoxic CAR+ T-cell lymphoma in the small intestine was reported in a patient who received cilta-cel therapy; numerous genetic alterations were identified ...

Follicular lymphoma, an indolent lymphoma ... Lunsumio targets the CD20 cells of FL and the CD3 cells of cytotoxic T cells, offering a viable solution for individuals with multiple relapses. B-Cell ...

The most well-known type of T cell therapy is CAR-T cell therapy, which has been approved for use by the US FDA since 2017 to treat blood cancers such as acute leukaemia, lymphoma and multiple ...

Peripheral T cell lymphoma, not otherwise specified (PTCL NOS ... Chemotherapy uses anti cancer (cytotoxic) drugs to destroy cancer cells. The drugs circulate throughout the body in your bloodstream.

Indolent CD4+ cytotoxic chimeric antigen receptor (CAR) T-cell lymphoma involving the small intestine was diagnosed in a patient who had previously received ciltacabtagene autoleucel (cilta-cel ...

"And, importantly, while lymphoma-bearing animals that received ... stages of the disease whose treatment requires a lot of cytotoxic T cell potential. In translating TES further toward human ...

The FDA has recognized the potential of SIRPant-M to treat patients with T-cell lymphoma. SIRPant-M is a novel cell therapy ... SIRPant-M works by targeting malignant cells by stimulating cytotoxic T ...